$1.79
-0.30 (-14.35%)
Open$2.07
Previous Close$2.09
Day High$2.08
Day Low$1.75
52W High$1,030.00
52W Low—
Volume—
Avg Volume197.2K
Market Cap48.71M
P/E Ratio—
EPS$-136.77
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+525.1% upside
Current
$1.79
$1.79
Target
$11.19
$11.19
$8.32
$11.19 avg
$14.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 4.88M | 4.46M | 5.44M |
| Net Income | -169,945 | -168,167 | -171,039 |
| Profit Margin | -3.5% | -3.8% | -3.2% |
| EBITDA | -214,177 | -200,655 | -244,682 |
| Free Cash Flow | -155,731 | -123,018 | -136,236 |
| Rev Growth | -8.5% | +21.3% | +21.2% |
| Debt/Equity | 0.77 | 0.64 | 0.80 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |